Ingredient or product comparison
Dosage Protocols: Systemic vs Topical Application
Systemic GHK-Cu administration (subcutaneous or intramuscular injection) achieves measurable plasma concentrations within 30–60 minutes, with a half-life of approximately 1.5–2 hours before hepatic metabolism. Research-grade peptide suppliers typically provide
This source-based comparison does not add ratings or recommend a winner.
- Systemic GHK-Cu administration (subcutaneous or intramuscular injection) achieves measurable plasma concentrations within 30–60 minutes, with a half-life of approximately 1.5–2 hours before hepatic metabolism. Research-grade peptide suppliers typically provide lyophilized GHK-Cu in 50mg or 100mg vials for reconstitution with bacteriostatic water. The standard protocol for scar reduction is 1–3mg injected subcutaneously once daily, preferably in the morning to align with peak fibroblast activity during the body's natural circadian repair cycle. Injecting more than 3mg does not accelerate results. Plasma saturation occurs around 150ng/mL, and exceeding this threshold increases renal copper clearance without additional receptor binding.
- Topical GHK-Cu formulations bypass first-pass hepatic metabolism and deliver the peptide directly to dermal fibroblasts, but penetration depth is the limiting factor. Human stratum corneum is approximately 10–20 micrometers thick and acts as a lipophilic barrier. GHK-Cu is hydrophilic and requires a carrier system to cross into the viable epidermis and upper dermis where scar remodeling occurs. Liposomal encapsulation increases dermal bioavailability by 4–6 times compared to aqueous solutions. At Real Peptides, we've seen consistent results with 2–5% GHK-Cu in a liposomal base applied twice daily. Morning and evening. To clean, dry scar tissue. Higher concentrations (above 5%) don't penetrate proportionally deeper and risk copper-induced irritation in sensitive individuals.
- The timing of application matters more than most protocols acknowledge. Scars undergo three distinct phases: inflammatory (0–4 days post-injury), proliferative (4 days to 3 weeks), and remodeling (3 weeks to 2 years). GHK-Cu is most effective during the remodeling phase when fibroblasts are still metabolically active but collagen synthesis has slowed. Starting GHK-Cu during the inflammatory phase can paradoxically worsen scarring by prolonging the proliferative phase. The peptide's pro-angiogenic effects stimulate blood vessel formation, which supports continued fibroblast activity rather than transitioning to organized remodeling. For surgical scars or controlled wounds, we recommend beginning GHK-Cu at week 3–4 post-injury, once the wound has fully epithelialized.